Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTAMENTO: Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in MS
NCT07074886Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoints: Area Under the Serum Concentration-time Curve Over the First 12 Weeks Post-dose and Maximum Serum Concentration at 12 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07074886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07074886.